HIV Microbicides and the Vaginal Microbiome
HIV 杀菌剂和阴道微生物组
基本信息
- 批准号:8143864
- 负责人:
- 金额:$ 43.84万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2008
- 资助国家:美国
- 起止时间:2008-09-05 至 2014-08-31
- 项目状态:已结题
- 来源:
- 关键词:AIDS preventionBenignBiologicalBiological AssayBiological SciencesCatalogingCatalogsCellsCharacteristicsClinicalClinical TrialsComplementary DNAComplexCulture TechniquesDataDevelopmentDoctor of PhilosophyEnvironmentEpidemicEquipment and supply inventoriesExhibitsFailureFundingFutureGastrointestinal tract structureGenesHIVHIV InfectionsHIV SeropositivityHealthHumanHydrogen PeroxideInflammationInflammatoryLeadLifeMaintenanceMeasuresMetabolicMethodsMicrobeMolecularMonitorNonoxynol 9Oligonucleotide MicroarraysOropharyngealPatientsPhasePhase III Clinical TrialsPhylogenetic AnalysisPlacebosPopulationPopulation DecreasesPrevalencePrincipal InvestigatorProductionProtocols documentationResearch SubjectsRiskSamplingSexual TransmissionSpecimenSwabTechniquesTechnologyTimeToxic effectUshercellVaginaVaginal DouchingVisitWomanbacteriocinbasecellulose sulfatedensitydesignhydroxyethylcellulosemeetingsmetagenomemicrobialmicrobial communitymicrobicidemicrobiomepandemic diseasephase 1 studyphase 3 studypre-clinicalpreventprogramsrRNA Genesresponsetechnology developmenttransmission processvaginal microbicide
项目摘要
Vaginal HIV microbicides offer great promise to reduce HIV transmission, but phase 3
microbicide trials have failed. In some studies, patients using the microbicides had
higher HIV transmission rates than did subjects using placebos. There is no clear
explanation for these failures, but one hypothesis holds that microbicides alter the
vaginal microbial flora in ways that increase inflammation or activate potential HIV host
cells, enhancing transmission. Studies examining the effects of microbicides on the
vaginal flora found few significant effects on the microbiome, but they used conventional
culture techniques. Recent studies using molecular, culture-independent techniques
showed that the flora in many human microbial environments, including the vagina, is
much more complex than previously appreciated and that conventional culture
techniques only detect a small fraction of the microbes in the environment. We propose
to use these new culture-independent techniques to explore the hypothesis that
microbicides alter the vaginal microbiome in ways that can potentially enhance HIV
transmission via these specific aims: 1) Examine the vaginal microbial flora before and
after microbicide application in a CONRAD repeat phase 1 study of nonoxynol-9 (N-9),
cellulose sulfate (CS), and placebo using Affymetrix PhyloChip microarrays 2) Examine
the portfolio of expressed genes in the vaginal microbiome before and after microbicide
application using microbial cDNA sequencing in the phase 1 study, and 3) Examine the
microbial species composition before and after microbicide application in the CONRAD
CS phase 3 study that failed using the PhyloChip and direct 16S rRNA gene
sequencing. The main milestone we propose to transition from the initial R21 phase of
the project to the R33 phase is the demonstration that microbicide use leads to a
significant alteration in the vaginal flora as assessed by the PhyloChip. Determining
whether microbicide application is associated with vaginal microbiome changes that
could enhance HIV transmission would aid understanding of the failure of the previous
phase 3 trials and would help future microbicide development efforts because, if harmful
changes in vaginal flora are associated with microbicide use, future microbicide
development efforts would require careful measures to avoid inducing potentially harmful
changes in the vaginal microbiome.
阴道HIV杀微生物剂为减少HIV传播提供了巨大的希望,但第3阶段
杀微生物剂试验失败了。在一些研究中,使用杀微生物剂的患者
艾滋病毒传播率高于使用安慰剂的受试者。没有明确
这些失败的解释,但一种假设认为,杀微生物剂改变了
阴道微生物植物群增加炎症或激活潜在的HIV宿主
细胞,增强传输。研究了杀微生物剂对
阴道植物群对微生物组几乎没有显着影响,但他们使用传统的
培养技术使用分子、非培养技术的最新研究
表明,包括阴道在内的许多人体微生物环境中的植物群,
比以前认识到的要复杂得多,
这些技术只能检测到环境中的一小部分微生物。我们提出
使用这些新的文化独立的技术来探索假设,
杀微生物剂改变阴道微生物组的方式可能会增强艾滋病毒
通过这些特定的目的传播:1)检查阴道微生物植物群之前,
在对壬苯醇醚-9(N-9)的CONRAD重复1期研究中应用杀微生物剂后,
硫酸纤维素(CS)和安慰剂,使用Affyphylchip微阵列2)检查
杀微生物剂前后阴道微生物组中表达基因的组合
在1期研究中使用微生物cDNA测序的应用,以及3)检查
康瑞德应用杀微生物剂前后的微生物种类组成
使用PhyloChip和直接16 S rRNA基因失败的CS 3期研究
测序我们建议从最初的R21阶段过渡到
R33阶段的项目是证明使用杀微生物剂会导致
根据PhyloChip评估,阴道植物群发生显著变化。确定
杀微生物剂的应用是否与阴道微生物组的变化有关,
可能会增加艾滋病毒的传播将有助于了解以前的失败,
这将有助于未来的杀微生物剂开发工作,因为如果有害的话,
阴道植物群的变化与杀微生物剂的使用有关,
发展努力需要采取谨慎措施,避免产生潜在的有害影响,
阴道微生物组的变化。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Steven L. Zeichner其他文献
Steven L. Zeichner的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Steven L. Zeichner', 18)}}的其他基金
Globally Appropriate Genome Reduced Killed Whole Bacterial HIV Vaccines
全球适用的基因组减少灭活全细菌 HIV 疫苗
- 批准号:
10672822 - 财政年份:2023
- 资助金额:
$ 43.84万 - 项目类别:
Pilot Study of Rectal Microbial Biomarkers for Appendicitis Diagnosis
用于诊断阑尾炎的直肠微生物生物标志物的初步研究
- 批准号:
9064769 - 财政年份:2015
- 资助金额:
$ 43.84万 - 项目类别:
Development of an in vivo screening technology for cancer vaccine immunogens
癌症疫苗免疫原体内筛选技术的开发
- 批准号:
8508685 - 财政年份:2011
- 资助金额:
$ 43.84万 - 项目类别:
Development of an in vivo screening technology for cancer vaccine immunogens
癌症疫苗免疫原体内筛选技术的开发
- 批准号:
8304214 - 财政年份:2011
- 资助金额:
$ 43.84万 - 项目类别:
Development of an in vivo screening technology for cancer vaccine immunogens
癌症疫苗免疫原体内筛选技术的开发
- 批准号:
8080672 - 财政年份:2011
- 资助金额:
$ 43.84万 - 项目类别:
WIRB - AN OPEN-LABEL, MULTIPLE-DOSE, CROSS-OVER STUDY TO EVALUATE: HIV
WIRB - 一项开放标签、多剂量、交叉研究来评估:HIV
- 批准号:
8167327 - 财政年份:2010
- 资助金额:
$ 43.84万 - 项目类别:
IMPAACT P1066: A PHASE I/II MULTICENTER, OPEN-LABEL, NONCOMPARATIVE STUDY OF
IMPAACT P1066:I/II 期多中心、开放标签、非比较研究
- 批准号:
8167353 - 财政年份:2010
- 资助金额:
$ 43.84万 - 项目类别:
PACTG P1047 SAFETY AND IMMUNOGENICITY OF QUADRIVALENT HUMAN PAPILLOMA VIRUS
PACTG P1047 四价人乳头瘤病毒的安全性和免疫原性
- 批准号:
8167345 - 财政年份:2010
- 资助金额:
$ 43.84万 - 项目类别:
PACTG P1047 SAFETY AND IMMUNOGENICITY OF QUADRIVALENT HUMAN PAPILLOMA VIRUS
PACTG P1047 四价人乳头瘤病毒的安全性和免疫原性
- 批准号:
7951109 - 财政年份:2008
- 资助金额:
$ 43.84万 - 项目类别:
IMPAACT P1066: A PHASE I/II MULTICENTER, OPEN-LABEL, NONCOMPARATIVE STUDY OF
IMPAACT P1066:I/II 期多中心、开放标签、非比较研究
- 批准号:
7951122 - 财政年份:2008
- 资助金额:
$ 43.84万 - 项目类别:
相似海外基金
Genome analysis-based prediction model development for response to stereotactic radiosurgery in benign brain tumors
基于基因组分析的预测模型开发,用于良性脑肿瘤立体定向放射外科治疗的反应
- 批准号:
23K08495 - 财政年份:2023
- 资助金额:
$ 43.84万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Clinical breast cancer risk prediction models for women with a high-risk benign breast diagnosis
高风险良性乳腺诊断女性的临床乳腺癌风险预测模型
- 批准号:
10719777 - 财政年份:2023
- 资助金额:
$ 43.84万 - 项目类别:
Environmentally Benign Precise Transformations of Alkenes by Chiral Chalcogenide Catalysts
手性硫属化物催化剂对环境无害的烯烃精确转化
- 批准号:
22KJ2498 - 财政年份:2023
- 资助金额:
$ 43.84万 - 项目类别:
Grant-in-Aid for JSPS Fellows
Learners to LeAders in benign Urology, benign Nephrology, and non-Cancer Hematology
良性泌尿外科、良性肾脏病学和非癌症血液学领域的学习者和领导者
- 批准号:
10726042 - 财政年份:2023
- 资助金额:
$ 43.84万 - 项目类别:
The role of estrogen receptor alpha in prostatic fibrosis contributing to benign prostatic hyperplasia
雌激素受体α在导致良性前列腺增生的前列腺纤维化中的作用
- 批准号:
10607151 - 财政年份:2023
- 资助金额:
$ 43.84万 - 项目类别:
Development of a medical device to resolve benign esophageal stricture by heating and traction
开发通过加热和牵引解决良性食管狭窄的医疗设备
- 批准号:
23H03765 - 财政年份:2023
- 资助金额:
$ 43.84万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Development of benign/malignant differentiation method for thyroid follicular tumor using organoids
利用类器官开发甲状腺滤泡性肿瘤良恶性鉴别方法
- 批准号:
23K08075 - 财政年份:2023
- 资助金额:
$ 43.84万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Mechanisms of p53 Engagement and Action at the Benign-to-Malignant Transition in Sporadic Tumorigenesis
p53在散发性肿瘤发生良性向恶性转变中的参与和作用机制
- 批准号:
10720034 - 财政年份:2023
- 资助金额:
$ 43.84万 - 项目类别:
I-Corps: Mitigating Multidrug Resistant Bacterial Infections with Biocompatible and Environmentally Benign Nanoantibiotics
I-Corps:利用生物相容性且对环境无害的纳米抗生素减轻多重耐药细菌感染
- 批准号:
2306943 - 财政年份:2023
- 资助金额:
$ 43.84万 - 项目类别:
Standard Grant
Identifying the role of the gut microbiome in the etiology of benign breast disease
确定肠道微生物组在良性乳腺疾病病因学中的作用
- 批准号:
10359959 - 财政年份:2022
- 资助金额:
$ 43.84万 - 项目类别:














{{item.name}}会员




